Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Merck (MRK) announced positive topline results from two Phase 3 trials (CORALreef HeFH and CORALreef AddOn) for enlicitide decanoate, an investigational oral PCSK9 inhibitor for adults with hyperlipidemia. The trials demonstrated statistically significant and clinically meaningful reductions in LDL-C compared to placebo and other oral non-statin therapies, meeting primary and key secondary endpoints, with no clinically meaningful differences in adverse events. If approved, enlicitide would be the first oral PCSK9 inhibitor, offering antibody-like efficacy in a daily pill, potentially addressing a significant unmet need in cardiovascular disease management.

Analysis

Merck has announced positive topline results from the initial two of three Phase 3 clinical trials, CORALreef HeFH and CORALreef AddOn, for its investigational oral PCSK9 inhibitor, enlicitide decanoate, intended for adults with hyperlipidemia. Both trials met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C). Specifically, enlicitide showed superiority over placebo in the CORALreef HeFH trial for patients with heterozygous familial hypercholesterolemia, and over other oral non-statin therapies like ezetimibe and bempedoic acid in the CORALreef AddOn trial for patients with hyperlipidemia on statin therapy. Crucially, there were no clinically meaningful differences in adverse events or serious adverse events reported in either trial. If approved, enlicitide, a novel macrocyclic peptide, has the potential to be the first marketed oral PCSK9 inhibitor in the U.S., offering antibody-like efficacy with the convenience of a daily pill. This development is significant given that atherosclerotic cardiovascular disease, for which LDL-C is a major modifiable risk factor, accounts for 85% of cardiovascular deaths worldwide. The comprehensive CORALreef Phase 3 program aims to enroll approximately 17,000 patients, indicating a robust development plan for this potentially transformative therapy.

Key Decisions for Investors

• The positive Phase 3 results for enlicitide represent a significant de-risking event for this pipeline candidate and strengthen Merck's position in the cardiovascular market, potentially leading to a first-in-class oral PCSK9 inhibitor.
• Investors should monitor for the full dataset presentation at future scientific congresses and subsequent regulatory submissions, as successful approval and commercialization could tap into the substantial market for hyperlipidemia management, currently impacting approximately 86 million adults in the U.S.
• The favorable safety profile, combined with demonstrated superior LDL-C reduction compared to some existing oral therapies, suggests enlicitide could achieve significant market penetration if further trial data from the larger CORALreef program, including CORALreef Lipids and CORALreef Outcomes, confirm these findings.